Compass Pathways Plc Stock Price, News & Analysis

COMPASS Pathways reported positive results from its phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression, showing rapid and sustained patient response with a single 25mg dose. Additionally, an open-label study indicated effectiveness when combined with SSRI antidepressants. The company is well-capitalized with a cash position of $273.2 million at year-end 2021. The end-of-phase II meeting with the FDA is scheduled for April 2022, with a phase III program expected to start in the second half of the year. New senior executives have also been appointed.

COMPASS Pathways (Nasdaq: CMPS), a mental health care company, is set to release its financial results for Q4 and the entire year of 2021, along with an update on recent developments, on February 24, 2022. A conference call will follow at 8:00 AM ET, accessible via phone and webcast. COMPASS is pioneering a new model of psilocybin therapy, recently achieving significant results in a large-scale clinical trial for treatment-resistant depression.

COMP360, its breakthrough therapy, is currently in further clinical trials for PTSD.

COMPASS Pathways plc (CMPS) has announced positive results from a phase I study on COMP360 psilocybin therapy, demonstrating its feasibility in simultaneous administration to healthy participants under 1:1 therapist support. Conducted by King's College London, the study involved 89 participants receiving different doses of psilocybin or placebo, with no serious adverse effects reported. The findings suggest potential for psilocybin therapy in treating severe mental health issues, paving the way for upcoming FDA discussions and plans for a phase III trial expected to begin in Q3 2022.

COMPASS Pathways (Nasdaq: CMPS) announced its addition to the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks biotech and pharmaceutical securities, making it significant for institutional investors. CEO George Goldsmith expressed pride in this achievement, which aims to enhance visibility as the company advances its COMP360 psilocybin therapy for mental health. This therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression and has shown statistically significant clinical trial results.

COMPASS Pathways (Nasdaq: CMPS) has appointed Matthew Owens as its new General Counsel and Chief Legal Officer, effective February 1, 2022. Owens joins from Novartis, where he was the Global Head of Legal, Digital. Concurrently, Lars Wilde, co-founder and Chief Business Officer, will transition to a senior advisory role from January 1, 2022. Under Wilde's leadership, COMPASS raised over $429 million and advanced its psilocybin therapy for mental health, which has received Breakthrough Therapy designation from the FDA.

COMPASS Pathways (Nasdaq: CMPS) announced positive results from its study of COMP360 psilocybin therapy in patients concurrently taking SSRIs. In this phase IIb trial, 19 patients treated with a 25mg dose had comparable outcomes to those who discontinued SSRIs before treatment. 42.1% of participants responded after three weeks, with an average MADRS score reduction of 14.9. Notably, no serious adverse events emerged. COMPASS is now preparing to meet with the FDA to finalize its phase III program planned to start in Q3 2022.

COMPASS Pathways plc (Nasdaq: CMPS) announced the appointment of Michael Falvey as Chief Financial Officer, effective January 1, 2022. He replaces Piers Morgan, who departs at year-end. Falvey has a robust background in finance, having previously led financial strategies at Karyopharm Therapeutics and other growth companies. His expertise will be vital as COMPASS advances its psilocybin therapy for treatment-resistant depression, especially following recent positive Phase IIb clinical trial results. The company has raised over $425 million and aims to transform mental health care.

COMPASS Pathways (Nasdaq: CMPS) announced positive results from its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Additional analyses validated prior findings, showing significant improvements in depression symptoms and overall patient functioning with a 25mg dose compared to 1mg. Outcomes measured at three weeks revealed a -6.6 difference on the MADRS scale (p<0.001). Safety analysis indicated that COMP360 was generally well-tolerated, with most adverse events resolving quickly. The company anticipates starting a pivotal phase III trial in 2022.